Diabetes causes the activation of the pro-ageing miRNA-34a in the human heart

Background: Secondary prevention medications (aspirin, other anti-platelet agents, statins, beta-blockers, angiotensin converting enzyme-inhibitors/angiotensin receptor blockers (ACE-I/ARBs)) following an Acute Coronary Syndrome (ACS) improve patients’ (pt) prognosis. The first National ACS audit (2002) identified a limited uptake of these medications. Subsequent audits in 2007 and 2012 allow comparison of the prescription rates over a decade. Methods: Over 14 days, in May 2002, 2007 and 2012, pts with suspected ACS admitted to a hospital in NZ were audited to assess clinical management. ‘Definite’ ACS pts were determined at discharge, after in-hospital investigations. We assessed discharge secondary prevention medication use in ACS survivors. Results: For ST-segment elevation myocardial infarction/ left bundle branch block (STEMI/LBBB) and Non-STEACS pts there have been significant increases in the discharge rates of secondary prevention medications (Table).